India, July 12 -- Strong earnings momentum continues to build for this pharmaceutical formulations company, which caters largely to the regulated US market. The latest quarterly numbers show broad-based revenue growth, expanding margins, and a sharp jump in profitability, backed by a three-year compounded profit growth rate of 155%. With a recent domestic acquisition and steady product approvals, the company is positioning itself for the next leg of growth.

Shares of Rubicon Research Limited, with a market capitalization of Rs.23,633 crore, closed at Rs.1,431.4 on Friday. The stock currently trades at a P/E ratio of 114.4.

Motilal Oswal's Recent Pick According to the brokerage report, Rubicon Research has joined Motilal Oswal's portfol...